Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares traded down 7.1% during trading on Friday . The stock traded as low as $0.23 and last traded at $0.26. 2,230,890 shares were traded during trading, an increase of 454% from the average session volume of 402,428 shares. The stock had previously closed at $0.28.
Several research firms have recently weighed in on BPTH. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective (down from $4.50) on shares of Bio-Path in a research report on Monday, November 13th. lowered their price objective on Bio-Path from $4.50 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, November 15th. Finally, ValuEngine lowered Bio-Path from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Bio-Path presently has an average rating of “Hold” and a consensus price target of $1.67.
Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). analysts expect that Bio-Path Holdings, Inc. will post -0.08 earnings per share for the current fiscal year.
Bio-Path Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
What are top analysts saying about Bio-Path Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Path Holdings Inc. and related companies.